Zobrazeno 1 - 10
of 451
pro vyhledávání: '"Matching-adjusted indirect comparison"'
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 11, Pp 3071-3081 (2024)
Abstract Introduction Despite advancements in the treatment of psoriasis (PsO), there are few head-to-head studies assessing comparative effectiveness of the newest therapies approved to treat PsO. Our objective was to assess the comparative clinical
Externí odkaz:
https://doaj.org/article/4674a01da9764f109764140e3aba0925
Autor:
David Cherney, Kerstin Folkerts, Paul Mernagh, Mateusz Nikodem, Joerg Pawlitschko, Peter Rossing, Neil Hawkins
Publikováno v:
Journal of Market Access & Health Policy, Vol 12, Iss 3, Pp 169-180 (2024)
This study aimed to close an evidence gap concerning the relative efficacy of finerenone versus SGLT2is in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Canagliflozin was selected as a proxy for the SGLT2i class. Patient-level
Externí odkaz:
https://doaj.org/article/dff937541dc9404db1fe3b6590a96398
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 10 (2024)
Aim: Diroximel fumarate (DRF), ozanimod (OZA) and interferon beta-1a (IFN) are disease-modifying therapies approved for the treatment of relapsing multiple sclerosis. No randomized trials have compared DRF versus OZA and IFN. We compared DRF versus
Externí odkaz:
https://doaj.org/article/6731514328ba4c679fdb9725da266113
Autor:
Walter P. Maksymowych, Howard Thom, Michael F. Mørup, Vanessa Taieb, Damon Willems, Nikos Lyris, Karl Gaffney
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 4, Pp 1023-1041 (2024)
Abstract Introduction A previous network meta-analysis established 16-week relative efficacy with bimekizumab, an inhibitor of interleukin (IL)-17F in addition to IL-17A, versus other treatments for patients with radiographic axial spondyloarthritis
Externí odkaz:
https://doaj.org/article/4b878f98b5e34d09a94b0e709d45235c
Autor:
Xenofon Baraliakos, Christopher D. Saffore, Eric B. Collins, Bhumik Parikh, Xiaolan Ye, Jessica A. Walsh
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 4, Pp 989-999 (2024)
Abstract Introduction With an increasing number of biologic/targeted synthetic disease-modifying antirheumatic drug options available for the treatment of active ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis, it is o
Externí odkaz:
https://doaj.org/article/7cdbb879755643368e68e033ae3c2279
Autor:
A. M. Lila, T. V. Dubinina, D. G. Tolkacheva, K. V. Sapozhnikov, N. A. Sableva, M. A. Morozova, P. S. Pukhtinskaia
Publikováno v:
Современная ревматология, Vol 18, Iss 2, Pp 33-40 (2024)
Objective: to compare the clinical efficacy of seniprutug (BCD-180) and adalimumab (ADA) in the treatment of adults with active radiographic axial spondyloarthritis (r-axSpA).Materials and methods. Based on the results of a previously conducted syste
Externí odkaz:
https://doaj.org/article/92f39961d54549a59f94611ef0ad985d
Autor:
Bérengère Macabeo, Arthur Quenéchdu, Samuel Aballéa, Clément François, Laurent Boyer, Philippe Laramée
Publikováno v:
Journal of Market Access & Health Policy, Vol 12, Iss 2, Pp 58-80 (2024)
Introduction: Health technology assessment (HTA) agencies express a clear preference for randomized controlled trials when assessing the comparative efficacy of two or more treatments. However, an indirect treatment comparison (ITC) is often necessar
Externí odkaz:
https://doaj.org/article/7ca5097be5844627ad4e12b2769b214e
Autor:
Tiago Torres, Anne Sohrt Petersen, Ulla Ivens, Albert Bosch Vilaro, John Stinson, José Manuel Carrascosa
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 4, Pp 983-992 (2024)
Abstract Introduction Tralokinumab and dupilumab are biological agents licensed for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients who are candidates for systemic treatment. However, no head-to-head studies of their effi
Externí odkaz:
https://doaj.org/article/effdcf10082344f191430a55ef10e778
Autor:
Richard G. Langley, MD, Chiranjeev Sanyal, PhD, Aaron Situ, MSc, Sarah Alulis, MSc, Fareen Hassan, MSc, Steve Peterson, MPH, Rachel E. Teneralli, PhD, Jennifer Lee, MBA, Barkha P. Patel, PhD, Tim Disher, PhD
Publikováno v:
JAAD International, Vol 15, Iss , Pp 165-167 (2024)
Externí odkaz:
https://doaj.org/article/22186959faf64799ac3671ec41d4d380
Publikováno v:
BMC Public Health, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Edaravone dexborneol and dl-3-n-butylphthalide are two innovative brain cytoprotective drugs from China that have been approved and widely prescribed for acute ischemic stroke, and the cost of the two drugs are partially paid by t
Externí odkaz:
https://doaj.org/article/b5a5af3c37724a4e9c302f0cf5c75877